title: Hypercalcemia in malignancies: treatment with dichloromethylene diphosphonate (Cl2MDP).
abstract: Eleven hypercalcemic patients affected by various kinds of cancer were treated with dichloromethylene diphosphonate (Cl2MDP), 400 mg diluted in 500 ml of saline solution, i.v., during 3 h. Drug administration normalized plasma calcium levels in all treated patients, within 72 h for patients with lung cancer; within a longer period for other kinds of cancer. Moreover, Cl2MDP also reduced calciuria in treated patients. The use of the drug was not followed by side effects and was also well tolerated in patients with kidney insufficiency.
authors.forename: N
authors.initials: N
authors.lastname: Conte
authors.forename: R
authors.initials: R
authors.lastname: Di Virgilio
authors.forename: I
authors.initials: I
authors.lastname: Roiter
authors.forename: L
authors.initials: L
authors.lastname: Caberlotto
mesh_terms: D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000150:complications / Q000378:metabolism / Q000556:secondary; D002118:Calcium / Q000378:metabolism; D004002:Clodronic Acid / Q000627:therapeutic use*; D004164:Diphosphonates / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D006934:Hypercalcemia / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications* / Q000378:metabolism; D013997:Time Factors
chemical_list: D004164:Diphosphonates; D004002:Clodronic Acid; D006909:Hydroxyproline; D002118:Calcium